Kesler Norman & Wride LLC Reduces Stock Holdings in Stryker Co. (NYSE:SYK)

Kesler Norman & Wride LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 16.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 8,691 shares of the medical technology company’s stock after selling 1,676 shares during the period. Kesler Norman & Wride LLC’s holdings in Stryker were worth $3,131,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Edgestream Partners L.P. boosted its stake in shares of Stryker by 216.1% during the 3rd quarter. Edgestream Partners L.P. now owns 3,430 shares of the medical technology company’s stock worth $1,239,000 after purchasing an additional 2,345 shares during the period. Kestra Investment Management LLC bought a new stake in Stryker in the third quarter worth about $346,000. Ascent Group LLC boosted its position in shares of Stryker by 2.0% during the third quarter. Ascent Group LLC now owns 3,867 shares of the medical technology company’s stock valued at $1,397,000 after buying an additional 77 shares during the period. Hilltop Holdings Inc. grew its stake in shares of Stryker by 161.2% during the third quarter. Hilltop Holdings Inc. now owns 3,479 shares of the medical technology company’s stock valued at $1,257,000 after buying an additional 2,147 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Stryker by 1.5% in the third quarter. Janus Henderson Group PLC now owns 1,969,757 shares of the medical technology company’s stock worth $711,594,000 after buying an additional 28,421 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on SYK shares. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Argus set a $450.00 price objective on shares of Stryker in a research report on Monday, February 3rd. Truist Financial raised their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Finally, Wells Fargo & Company boosted their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Stock Up 0.3 %

Shares of Stryker stock opened at $373.20 on Wednesday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The firm’s 50 day moving average price is $383.41 and its 200-day moving average price is $374.43. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $142.45 billion, a P/E ratio of 48.09, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 EPS. On average, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.